百诚医药(301096.SZ)创新药BIOS-0618片获临床试验批准

智通财经
03 Apr

智通财经APP讯,百诚医药(301096.SZ)公告,公司近日收到国家药品监督管理局(NMPA)临床试验批准通知书,公司自主研发的创新药BIOS-0618片将开展临床试验研究。本品此前已获得适用于神经病理性疼痛治疗的临床试验批准,本次为新增适应症获批,新增适应症为:阻塞性睡眠呼吸暂停综合征(OSA)患者日间过度思睡。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."